<DOC>
	<DOCNO>NCT00736190</DOCNO>
	<brief_summary>The purpose study evaluate antiviral activity safety tenofovir disoproxil fumarate ( TDF ) Asian-American adult ( self-reported Asian descent , live United States ) chronic hepatitis B infection . All participant receive active treatment TDF 48 week .</brief_summary>
	<brief_title>A Study Evaluate Tenofovir Disoproxil Fumarate ( DF ) Asian-American Adults With Chronic Hepatitis B Infection</brief_title>
	<detailed_description>Efficacy TDF evaluate reduction serum HBV DNA , change liver enzyme , generation antibody virus . Safety assess evaluate adverse event , laboratory abnormality , development drug resistance mutation .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Male female AsianAmerican , define person selfreported Asian ancestry reside United States ( US ) 18 75 year age , inclusive Documented chronic HBV infection , define positive serum HBsAg =/ &gt; 6 month HBV DNA =/ &gt; 10,000 copies/mL ( PCR method ) ALT &gt; ULN &lt; /= 10 Ã— ULN screen within past 12 month prior screen Willing able provide write informed consent Negative serum betahuman chorionic gonadotropin ( HCG ) pregnancy test ( female childbearing potential ) Estimated glomerular filtration rate ( creatinine clearance ) =/ &gt; 60 mL/min/1.73m^2 CockcroftGault equation Adequate hematologic function ( absolute neutrophil count =/ &gt; 1,500/mm^3 ; hemoglobin =/ &gt; 10.0 g/dL ) No prior TDF therapy ; participant may take &lt; 12 week oral antiHBV therapy , last dose =/ &gt; 16 week prior screen ; participant may receive prior interferon , must discontinue interferon therapy =/ &gt; 6 month prior screen Participants meet follow exclusion criterion enrol study . Pregnant woman , woman breast feed believe may wish become pregnant course study . Males females reproductive potential willing use effective method contraception study . For male , condom use female , barrier contraception method use combination one form contraception . Decompensated liver disease define direct ( conjugate ) bilirubin &gt; 1.2 X ULN , prothrombin time ( PT ) &gt; 1.2 X ULN , platelets &lt; 150,000/mm3 , serum albumin &lt; 3.5 g/dL Prior history clinical hepatic decompensation ( eg , ascites , jaundice , encephalopathy ) variceal hemorrhage Receipt prior TDF treatment Receipt =/ &gt; 12 week oral antiHBV nucleoside/nucleotide therapy , receipt ANY oral antiHBV treatment &lt; 16 week prior screen Receipt interferon ( pegylated ) therapy within 6 month Screening Visit alphafetoprotein &gt; 50 ng/mL Evidence hepatocellular carcinoma ( HCC ) Coinfection human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) History significant renal disease ( eg , nephrotic syndrome , renal dysgenesis , polycystic kidney disease , congenital nephrosis , acute tubular necrosis , renal disease ) History significant bone disease ( eg , osteomalacia , chronic osteomyelitis , osteogenesis imperfecta , osteochrondroses , multiple bone fracture ) Significant cardiovascular , pulmonary neurological disease Evidence gastrointestinal malabsorption syndrome may interfere absorption orally administer medication History solid organ bone marrow transplantation Ongoing therapy following : nephrotoxic agent , competitor renal excretion ( eg , probenecid ) , systemic chemotherapeutic agent , systemic corticosteroid , Interleukin2 ( IL2 ) immunomodulating agent , investigational agent ( except express approval Sponsor ) ; administration medication must discontinue least 30 day prior Baseline Visit duration study period Known hypersensitivity study drug , metabolite , formulation excipients Any condition ( include alcohol substance abuse ) prior therapy , opinion Investigator , would make participant unsuitable study unable comply dosing requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Tenofovir disoproxil fumarate</keyword>
	<keyword>Tenofovir DF</keyword>
	<keyword>Asian-American</keyword>
</DOC>